Why Is Moderna Stock Trading Lower On Wednesday?
Portfolio Pulse from Vandana Singh
Moderna's stock is trading lower due to concerns over the declining efficacy of its RSV vaccine compared to competitors GSK and Pfizer. The CDC's Advisory Committee on Immunization Practice is set to review vaccine recommendations, and Moderna's data shows a significant drop in efficacy over time. GSK and Pfizer's vaccines have shown better long-term efficacy, with GSK securing a larger market share and Pfizer winning a major contract in the U.K.
June 26, 2024 | 4:54 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
CVS Health benefits from its contracts with GSK for the Arexvy RSV vaccine, which has shown better long-term efficacy compared to Moderna's vaccine. This strengthens CVS's position in the retail pharmacy market.
CVS's contracts with GSK for a superior RSV vaccine enhance its market position, likely leading to a positive impact on its stock price.
CONFIDENCE 85
IMPORTANCE 60
RELEVANCE 50
POSITIVE IMPACT
GSK's RSV vaccine, Arexvy, has shown better long-term efficacy compared to Moderna's mRESVIA, securing a larger market share and contracts with retail pharmacies. This positions GSK favorably in the RSV vaccine market.
GSK's superior vaccine efficacy and market positioning provide a competitive advantage, likely leading to a positive impact on its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 70
POSITIVE IMPACT
Pfizer's RSV vaccine, Abrysvo, demonstrates strong long-term efficacy and has secured a major contract with the U.K. This positions Pfizer well in the RSV vaccine market, potentially boosting its stock.
Pfizer's strong vaccine efficacy and significant contract win in the U.K. enhance its market position, likely leading to a positive impact on its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 70
NEGATIVE IMPACT
Moderna's stock is down 6.98% due to concerns over the declining efficacy of its RSV vaccine, mRESVIA, compared to competitors GSK and Pfizer. The CDC's upcoming review of vaccine recommendations adds to the uncertainty.
The significant drop in vaccine efficacy over time and the upcoming CDC review create uncertainty for Moderna's RSV vaccine, leading to a negative impact on its stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100